Favorable preliminary safety profile of NVL-520 suggests potential for a highly ROS1-selective, TRK
sparing design, with no dose-limiting toxicities, treatment-related serious adverse events, treatment-
related dizziness, or adverse events leading to treatment reductions or discontinuations as of the
data cut-off date
Encouraging preliminary signs of activity observed across all dose levels in heavily pre-treated
patients with ROS1-positive NSCLC, including in subgroups of patients with G2032R resistance
mutation or with brain metastases
Company to host conference call today at 8:30 am EDT
Nuvalent will host a live webcast and conference call today at 8:30am EDT to discuss these results. The event is accessible through the "Events" section of the Investors page of www.nuvalent.com or by dialing (866) 652-5200 (domestic) or (412) 317-6060 (international) and referring to conference ID 10171503. A replay and accompanying slides will be archived on the Nuvalent website for 30 days.
https://finance.yahoo.com/news/nuvalent-reports-preliminary-phase-1-040100476.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.